Diagnosis & Disease Information

Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.

In all, 32 patients had a response, translating to an ORR of 66.7%.

The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).

The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.

The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.